China Refuses Paxlovid Coverage Beyond March, Despite Strong Demand
Local Production Planned
China has rejected extending insurance coverage for Pfizer’s Paxlovid despite the US company's plans to continue supplying the oral COVID-19 antiviral, including through local manufacturing, amid strong demand and increasing severe infections in the country.
